Several oncology companies announced key trial milestones this week across the landscape of both blood cancers and solid ...

For years, scientists have hoped to harness the immune system to attack cancer using a group of drugs known as CD40 agonist ...

In this video from the American Society of Retina Specialists annual meeting, Charles C. Wykoff, MD, PhD, FASRS, discusses ...

More than two years after the Food and Drug Administration held a public workshop on measuring overall survival (OS) in ...

Vascular toxicity associated with cancer therapies is a leading cause of cardiovascular adverse events in patients with ...

In this episode presented by Cresset, BioSpace’s head of insights Lori Ellis discusses clinical trial fail rates and AI’s ...

Synthetic generation replicates key clinical patterns from real-world data, enabling valid analyses with fewer patients.

Private equity firm THL Partners has agreed to buy a majority stake in Headlands Research, a U.S.-based network of clinical ...

Dr. Hussein Tawbi, who works for MD Anderson in Houston, said there are two things he hopes people take away from the story ...

By Rishika Sadam and Bhanvi Satija (Reuters) -Japanese drugmaker Takeda Pharmaceutical is exploring the option of conducting ...

Dr. Miller said he was optimistic that the clinical trial results would support an F.D.A. approval, but if or when that might happen is unclear, especially given recent changes at the agency.